LifeVantage Reports Steep Q2 Revenue & Earnings Decline, Significant Cash Burn, and Underperforming Acquisition

summarizeSummary

LifeVantage Corporation reported a substantial decline in Q2 2026 revenue and net income, alongside a significant reduction in active accounts and a sharp decrease in cash from operations. The company also disclosed an inventory obsolescence charge and an earnout reversal for a recent acquisition, indicating operational challenges.

check_boxKey Events · Earnings and Guidance · LFVN

• Q2 Revenue Plunges 27.8%

  Net revenue for the three months ended December 31, 2025, decreased by 27.8% to $48.9 million from $67.8 million in the prior year period.

• Net Income Drops 89.2%

  Net income for the three months ended December 31, 2025, fell by 89.2% to $0.3 million from $2.6 million in the prior year period.

• Active Accounts Decline 21.2%

  Total active accounts decreased by 21.2% to 115,000 as of December 31, 2025, compared to 146,000 in the prior year, indicating a shrinking customer and consultant base.

• Significant Cash Burn and Reduced Operating Cash Flow

  Cash and cash equivalents decreased by nearly 50% ($10.02 million) in six months, from $20.2 million on June 30, 2025, to $10.2 million on December 31, 2025. Net cash provided by operating activities for the six months ended December 31, 2025, plummeted by 94.3% to $0.5 million from $8.6 million in the prior year.

auto_awesomeAnalysis · LFVN · Life Sciences

LifeVantage Corporation's Q2 2026 financial results reveal a severe deterioration in performance, with revenue falling by 27.8% and net income by 89.2% compared to the prior year. This sharp decline is compounded by a 21.2% reduction in total active accounts, signaling fundamental weakness in its direct selling model. The company experienced a significant cash burn, with cash and cash equivalents decreasing by nearly 50% in six months and net cash from operating activities plummeting by 94.3%. Further negative indicators include a $2.4 million inventory obsolescence charge related to its MindBody GLP-1 System and a $0.3 million earnout reversal for the recent LoveBiome acquisition due to lower-than-forecasted revenue performance. While the company maintains it has sufficient liquidity for the next 12 months, the rapid cash depletion and operational challenges suggest a precarious financial position, especially given the stock is trading near its 52-week low. Investors should monitor the company's ability to reverse these trends and manage its liquidity.